Relay Is Up 118% and Now Selling at Almost 390x Sales. Let's Talk About It.

Here's the thing nobody in the Relay Therapeutics (RLAY) crowd will tell you out loud: the stock has ripped ~194% over the trailing year and ~118% year-to-date, and it is now trading at nearly 390 times sales. Not the biotech group. Not the peers. Nearly 390x. On a company that took in roughly $10 million in revenue over the last twelve months and lost nearly $290 million doing it.

That's not a valuation. That's a belief system, and it's a fragile one.

Let me lay out the board, because the setup is genuinely interesting and I don't want you buying a narrative without seeing the whole thing.

What the business actually is

Relay is a clinical-stage, small-molecule precision-medicine company out of Cambridge, Massachusetts. It leans on a platform called Dynamo — structural biology, computational modeling, machine learning — to hit proteins people have traditionally given up on. Its marquee asset is zougalisib, pitched as the first pan-mutant selective PI3Kα inhibitor in clinical development. There's a second weapon, atirmociclib, and a third leg, RLY-8161, an NRAS-selective inhibitor in melanoma.

On paper, this is a legitimate, well-funded biotech. It reported $910.9 million in cash, cash equivalents, and investments at June 30, 2026, with management pointing to runway into 2029. It raised about $316 million in gross proceeds through a May 2026 follow-on offering. It signed a clinical supply deal with Pfizer for atirmociclib — Relay keeps global rights to zougalisib. It selected a triplet regimen (zougalisib plus atirmociclib) as the go-forward front-line breast-cancer play and says a Phase 3 first-line trial should kick off in early 2027. It's enrolling Phase 3 ReDiscover-2 in second-line breast cancer and touts a 60% volumetric response rate in vascular anomalies.

Solid dossier. No question.

The problem isn't the pipeline. It's the price.

Here's where I part ways with the cheerleaders.

The stock closed around $18.41 recently and sits near there now, but the market cap prints and the multiples tell a story of a market that has priced in a lot of good news and then some. We're talking roughly $4 billion to $4.03 billion capitalized, a price-to-book near 4.5x against a biotech group average closer to 2x, and that absurd price-to-sales figure hovering around 390. A Seeking Alpha dossier pegs a risk-adjusted fair value at $13.53 with a Hold rating — which means the bullish case is already baked into a number well below where the shares trade.

And notice the momentum data underneath all this euphoria: down nearly 5% over the past month, down ~3.6% over the quarter. The stock ran hard and has been quietly digesting. That's not a teardown yet. But when you're buying at 390x sales, the margin for a single misstep is paper-thin.

The two things I'd actually watch

The earnings date is a mess. Two independent sources disagree on both the day and the session, though one of them—November 5, 2026—has been confirmed as an upcoming earnings event. One camp says November 5 after the close; another, flagged "confirmed," says November 11 before the open. I'd treat the calendar as unconfirmed until the company says so. I'd also expect another revenue miss — the second-quarter print came in well below consensus on both EPS and revenue, and this is a company still running on partnership and development income rather than real sales.

The catalyst calendar is binary. Enrollment updates on ReDiscover-2, a regulatory design update on the first-line trial, vascular-anomalies readouts — all penciled in by year-end 2026. Early-2027 trial initiation. First-half 2027 triplet-combination data. These are the moves that could justify the premium or quietly deflate it.

My read

I like the company. I don't love the price, and I refuse to pretend a 390x-sales multiple and a near-4.5x book multiple are the same kind of bet. What's priced in here is execution on every front — the Pfizer supply chain holding, the first-line trial launching, the triplet data landing. That's a bull case that assumes success, compounded.

The cash runway takes away the near-term survival fear, which is why the stock has been able to run at all. But that same runway is a double-edged sword: when there's no financing overhang, the only thing left to disappoint you is the science. And the science is, by definition, not finished.

So here's the honest take: Relay is a high-conviction, high-multiple, binary-outcome story dressed up as a compounder. If you're in it, you're betting on 2027, not 2026. If you're chasing it, you're paying up for certainty that doesn't exist yet. Neither of those is wrong. Both of them require you to know which one you're actually doing.

Buy the rumor at 390x sales and then wonder why the stock dropped 5% in a month — that's on you.